Ascelia_Pharma

Chimeric Therapeutics

AU: CHM

AU$61.9m market cap

AU$0.32 last close

Chimeric Therapeutics, which is based in Australia and focused on oncology, recently went public on the ASX. Lead programme CLTX-CAR T is in Phase I for the treatment of GBM. This is an innovative approach for an unmet medical need. Beyond GBM, the technology may have applicability for other tumours such as melanoma.

Investment summary

Chimeric Therapeutics is a newly formed Australia-based biotechnology company with a focus on oncology that has recently gone public on the ASX. In September, Chimeric announced that it in-licensed CLTX-CAR T, currently in Phase I. The study dosed its first patient in September 2020 (two patients i total have been dosed so far) and expects to enrol approximately 18 patients with recurrent/progressive glioblastoma. The goal of the study will be to determine a maximum tolerated dose schedule and a recommended dosing plan for the Phase II trial as well as to get initial evidence of efficacy and assess safety.

Y/E Jun
Revenue (A$m)
EBITDA (A$m)
PBT (A$m)
EPS (c)
P/E (x)
P/CF (x)
2019A N/A N/A N/A N/A N/A N/A
2020A 0.0 (0.1) (0.1) (6200.80) N/A N/A
2021E 0.0 (16.3) (16.3) (4.85) N/A N/A
2022E 0.0 (11.3) (11.3) (3.32) N/A N/A
Industry outlook

GBM accounts for 60% of brain tumours in adults and continues to have a poor prognosis with five-year survival of only 5.1%. Surgery, radiation and temozolomide are the current standards of care but patients typically recur due to the infiltrative nature of the GBM tumours.

Last updated on 25/02/2021
Register to receive research on Chimeric Therapeutics as it is published
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (A$m) 19.9
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (14.9) N/A N/A
Relative* (14.8) N/A N/A
52-week high/low A$0.4/A$0.3
*% relative to local index
Key management
Paul Hopper Executive Chairman